Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
| Business Activity | PASS |
| Debt Ratio | N/A |
| Cash Ratio | N/A |
| Receivables Ratio | N/A |
| Revenue Ratio | N/A |
| Overall | INSUFFICIENT DATA |
$890.7M
2.77
13
$1.4M
1.60
19.32
0.2%
103
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($31.46, 13 analysts) | |||
| 10 | $215.80 | +$98.80 (46%) | 3.0R |
| 50 | $1,079.00 | +$494.00 (46%) | 3.0R |
| 100 | $2,158.00 | +$988.00 (46%) | 3.0R |
- Elevated short interest (19.32 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| HQH | 0.404 |
| IMNM | 0.389 |
| SYRE | 0.382 |
| ORKA | 0.371 |
| CGON | 0.362 |
| Ticker | Correlation |
|---|---|
| AFIB | -0.275 |
| ALSREIT.KL | -0.127 |
| IMB.L | -0.120 |
| 4200.SR | -0.116 |
| SUKOON.AE | -0.108 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.